The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Boytsov S.A.

Chazov National Medical Research Center of Cardiology

Piradov M.A.

Research Center of Neurology

Tanashyan M.M.

Research Center of Neurology

Voznyuk I.A.

Ezhov M.V.

National Medical Research Center of Cardiology

Oshchepkova E.V.

National Medical Research Center of Cardiology

Sergienko I.V.

National Medical Research Center of Cardiology

Shamalov N.A.

Pirogov National Research Medical University;
Federal Center for Brain Research and Neurotechnologies

Skiba Ya.B.

Pavlov First Saint Petersburg State Medical University

Yanishevsky S.N.

Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation

Topical issues of adequate control of dyslipidemia in the prevention of acute and recurrent cerebral circulatory disorders of ischemic type

Authors:

Boytsov S.A., Piradov M.A., Tanashyan M.M., Voznyuk I.A., Ezhov M.V., Oshchepkova E.V., Sergienko I.V., Shamalov N.A., Skiba Ya.B., Yanishevsky S.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(5): 7‑10

DOI: 10.17116/jnevro20221220517

Views: 1593

Downloaded: 35

Download PDF (RU)
Contact the author
Table of contents

TOPICAL ISSUES OF ADEQUATE CONTROL OF DYSLIPIDEMIA IN THE PREVENTION OF ACUTE AND RECURRENT CEREBRAL CIRCULATORY DISORDERS OF ISCHEMIC TYPE
TOPICAL ISSUES OF ADEQUATE CONTROL OF DYSLIPIDEMIA IN THE PREVENTION OF ACUTE AND RECURRENT CEREBRAL CIRCULATORY DISORDERS OF ISCHEMIC TYPE

To cite this article:

Boytsov SA, Piradov MA, Tanashyan MM, et al. . Topical issues of adequate control of dyslipidemia in the prevention of acute and recurrent cerebral circulatory disorders of ischemic type. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(5):7‑10. (In Russ.)
https://doi.org/10.17116/jnevro20221220517

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Topi­cal application of hypo­tensive drugs for the prevention of intraocular pressure elevation after intravitreal inje­ctions of anti-VEGF drugs. Russian Annals of Ophthalmology. 2024;(2-2):73-79
The impact of arti­ficial inte­lligence on double reading of mammograms. Russian Journal of Preventive Medi­cine. 2024;(5):32-37
Methods of cost-effectiveness evaluation of endo­vascular patent fora­men ovale closure for seco­ndary prevention of cryptogenic stroke. Russian Journal of Preventive Medi­cine. 2024;(6):105-110
Arti­ficial inte­lligence in dermatology: oppo­rtunities and prospects. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(3):246-252
Brain-derived neurotrophic factor in the acute and early reco­very period of ischemic stroke: the role of nocturnal hypo­xemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):72-78
Indi­cators of cognitive impairment of varying seve­rity in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):14-20
Repeated ischemic stro­kes due to infe­ctious arte­ritis of both inte­rnal caro­tid and basi­lar arte­ries as a complication of sphe­noiditis and otitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):31-37
Cases of successful thro­mbus extraction in ischemic stroke asso­ciated with the new coro­navirus infe­ction COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):38-46
On the issue of opti­mizing protein and energy supply for patients with acute cere­brovascular acci­dent. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):51-55
Place of oligopeptide H-Met-Glu-His-Phe-Pro-Gly-Pro-OH in the therapy and reha­bilitation of patients with ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):56-63

Ischemic stroke (IS) is one of the main causes of death and permanent disability. Reducing the burden of stroke is possible if effective preventive measures are provided. The possibilities of correcting lipid metabolism as an important measure aimed at preventing IS are analyzed.

Keywords:

ischemic stroke
cardiovascular risk factors
cholesterol
prevention

Authors:

Boytsov S.A.

Chazov National Medical Research Center of Cardiology

Piradov M.A.

Research Center of Neurology

Tanashyan M.M.

Research Center of Neurology

Voznyuk I.A.

Ezhov M.V.

National Medical Research Center of Cardiology

Oshchepkova E.V.

National Medical Research Center of Cardiology

Sergienko I.V.

National Medical Research Center of Cardiology

Shamalov N.A.

Pirogov National Research Medical University;
Federal Center for Brain Research and Neurotechnologies

Skiba Ya.B.

Pavlov First Saint Petersburg State Medical University

Yanishevsky S.N.

Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation

Received:

10.02.2022

Accepted:

14.02.2022

List of references:

  1. Koton S, Rexrode KM. Trends in stroke incidence in the United States. Neurology. 2017;89(10):982-983.  https://doi.org/10.1212/WNL.0000000000004342
  2. Geraskina LA, Alieva MM, Fonyakin AV, et al. Repeated ischemic stroke with atrial fibrillation: frequency, heterogeneity, prevention. Atherothrombosis = Atherothrombosis. 2020;2:7-16. (In Russ.) https://doi.org/10.21518/2307-1109-2020-2-7-16
  3. Parfenov VA. Faktory riska povtornogo ishemicheskogo insul’ta i ego profilaktika. Neurology, Neuropsychiatry, Psychosomatics. 2010;2(3):40-46. (In Russ.). https://doi.org/10.14412/2074-2711-2010-99
  4. Yanishevskiy SN, Skiba IB, Polushin AY. Statins in patients with acute ischemic stroke: when we should start therapy? Arterial’naya Gipertenziya. 2021;27(1):16-28. (In Russ.) https://doi.org/10.18705/1607-419X-2021-27-1-16-28
  5. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Pedersen TR, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. https://doi.org/10.1016/S0140-6736(10)61350-5
  6. Amarenco P, Bogousslavsky J, Callahan A. 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559.  https://doi.org/10.1056/NEJMoa061894
  7. Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:23872397.
  8. Fulcher J, O’Connell R, Voysey M, et al. Cholesterol Treatment Trialists Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:13971405.
  9. Amarenco P, Kim JS, Labreuche J, et al. A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med. 2020;382(1):9.  https://doi.org/10.1056/NEJMoa1910355
  10. Diagnosis and correction of lipid metabolism disorders for the prevention of atherosclerosis. Russ Recommendations VII revision, 2020. Atherosclerosis Dyslipidemia. 2020;1:7-44. (In Russ.).
  11. ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205.  https://doi.org/10.1016/j.atherosclerosis.2019.08.014
  12. Huisa BN, Stemer AB, Zivin JA. Atorvastatin in stroke: a review of SPARCL and subgroup analysis. Vasc Health Risk Manag. 2010;6:229-236.  https://doi.org/10.2147/vhrm.s6795
  13. Mach F, Ray KK, Wiklund O, et al. European Atherosclerosis Society Consensus Panel. Adverse effects of statin therapy: perception vs the evidence — focus on glucose, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2019;39:2526-2539. https://doi.org/10.1093/eurheartj/ehy182
  14. Sabatine MS, Giugliano RP, Keech A et al. FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. https://doi.org/10.1056/NEJMoa1615664
  15. Newman CB, Preiss D, Tober JA, et al. and American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council (2019). Statin Safety and Associated Adverse Events: A Scientific Statement the American Heart Association. Arteriosc Thromb Vasc Biol. 2019;39(2):38-81.  https://doi.org/10.1161/ATV.0000000000000073
  16. Arif H, Aijaz B, Islam M, et al. Drug compliance after stroke and myocardial infarction: a comparative study. Neurology India. 2007;55(2):130-135.  https://doi.org/10.4103/0028-3886.32783
  17. Al Shaikh S, Quinn T, Dunn W, et al. Predictive factors of non-adherence to secondary preventative medication after stroke or transient ischaemic attack: A systematic review and meta-analyses. Eur Stroke J. 2016;1(2):65-75.  https://doi.org/10.1177/2396987316647187
  18. Kosmas CE, Muñoz Estrella A, Skavdis A, et al. Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential. Ther Clin Risk Manag. 2020;16:1031-1037. https://doi.org/10.2147/TCRM.S230592
  19. Aboyans V, Ricco JB, Bartelink M, et al. ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763-816.  https://doi.org/10.1093/eurheartj/ehx095
  20. Order of the Ministry of Health of the Russian Federation No. 1n dated January 9, 2020 «On Approval of the List of Medicines for Medical Use to Provide for One Year on an Outpatient Basis for Persons Who have Suffered acute cerebral Circulation Disorder, Myocardial Infarction, and who have undergone coronary artery bypass grafting, coronary artery angioplasty with Stenting and catheter Ablation according to about cardiovascular diseases». (In Russ.).

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.